产品名称
Anti-BCRP Antibody, clone BXP-34, culture supernatant, clone BXP-34, Chemicon®
biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
BXP-34, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunocytochemistry: suitable
immunohistochemistry: suitable
input
sample type hematopoietic stem cell(s)
sample type neural stem cell(s)
isotype
IgG1
suitability
not suitable for Western blot
not suitable for immunohistochemistry (Paraffin)
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... ABCG2(9429)
Analysis Note
Control
MCF-7 cells
MCF-7 cells
Application
Detect BCRP using this Anti-BCRP Antibody, clone BXP-34 validated for use in IC, IH.
Immunocytochemistry: 1:20 - 1:50 on acetone fixed cytospin preparations
Immunohistochemistry: 1:20 on acetone fixed frozen tissue sections
Not suitable for paraffin-embedded tissues or for Western blotting
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 1:20 on acetone fixed frozen tissue sections
Not suitable for paraffin-embedded tissues or for Western blotting
Optimal working dilutions must be determined by end user.
Research Category
Stem Cell Research
Stem Cell Research
Research Sub Category
Hematopoietic Stem Cells
Hematopoietic Stem Cells
Biochem/physiol Actions
This antibody reacts with an internal epitope of the Breast Cancer Resistance Protein (BCRP), a 70 kDa transmembrane half-transporter which is involved in multidrug resistance. The antibody does not cross-react with human MDR1, MRP1, MRP2 or MRP5 gene products.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
70 kDa
The 72 kDa breast cancer resistance protein (BCRP) is the second member of the subfamily G of the human ATP binding cassette (ABC) transporter superfamily and thus also designated as ABCG2. BCRP is a half-transporter consisting of only 1 nucleotide binding domain followed by 1 membrane-spanning domain. Current experimental evidence suggests that BCRP may function as a homodimer or homotetramer. Overexpression of BCRP is associated with high levels of resistance to a variety of anticancer agents. BCRP expression has been detected in a large number of hematological malignancies and solid tumors, indicating that this transporter may play an important role in clinical drug resistance of cancers. In addition to its role to confer resistance against chemotherapeutic agents, BCRP actively transports structurally diverse organic molecules, conjugated or unconjugated, such as estrone-3-sulfate, 17-β-estradiol 17-(β-D-glucuronide), and methotrexate. BCRP is highly expressed in the placental syncytiotrophoblasts, in the apical membrane of the epithelium in the small intestine, in the liver canalicular membrane, and at the luminal surface of the endothelial cells of human brain microvessels. This strategic and substantial tissue localization indicates that BCRP also plays an important role in absorption, distribution, and elimination of drugs that are BCRP substrates.
Immunogen
The Mitoxanthrone resistant, BCRP-overexpressing cell line MCF7-MR.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Liquid containing 0.7% BSA and 0.1% sodium azide.
Preparation Note
Maintain refrigerated at 2-8°C for up to 6 months. For long-term storage store at -20°C.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
Wen Jing et al.
Oncology letters, 20(6), 309-309 (2020-10-24)
Most patients with advanced leukemia eventually die from multidrug resistance (MDR). Chemotherapy-resistant leukemia cells may lead to treatment failure and disease relapse. Overexpression of ATP-binding cassette subfamily G member 2 (ABCG2) leads to MDR, which serves as a potential biomarker
Maria Paprocka et al.
European journal of haematology, 99(5), 415-422 (2017-08-15)
It is well established that expression of multi-drug resistance (MDR) proteins (MDR1, BCRP, MDR3, MRP1, and LRP) in leukemic blasts correlates with acute myeloid leukemia (AML) patients' clinical response. Assuming that leukemic stem cells (LSC) are resistant to chemotherapy and
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持